Singapore, Feb. 25 -- China-based WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced the signing of an expanded Memorandum of Understanding (MoU) with South Korea-based LigaChem Biosciences, Inc., a leader in the development of innovative ADC therapies targeting cancer and other serious diseases.

This new agreement broadens the scope of the ongoing collaboration, further accelerating the development of next generation innovative ADC therapies.

Under the terms of the expanded MoU, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of Lig...